Skip to main content
Top
Published in: Journal of Diabetes & Metabolic Disorders 1/2014

Open Access 01-12-2014 | Research article

Serum HDL-C level of Iranian adults: results from sixth national Surveillance of Risk Factors of Non-Communicable Disease

Authors: Mostafa Hosseini, Iman Navidi, Mahmoud Yousefifard, Ramin Heshmat, Jalil Koohpayehzadeh, Fereshteh Asgari, Koorosh Etemad, Ali Rafei, Mohammad Mehdi Gouya

Published in: Journal of Diabetes & Metabolic Disorders | Issue 1/2014

Login to get access

Abstract

Background

Reduced level of high-density lipoprotein-cholesterol (HDL-C) is shown to be in association with the risk of coronary artery disease (CAD), metabolic syndrome, and chronic renal disease. Lack of a national representative research for assessing the level of HDL-C among Iranian adults, which is essential for health policy makers, was the motivation for this study.

Methods

HDL-C levels of 4,803 Iranian adults aged 25–64 years old were measured by sixth national Surveillance of Risk Factors of Non-Communicable Disease (SuRFNCD) in 2011. Data were entered into STATA 12 software and were analyzed using fractional polynomial model and other statistical methods.

Results

In average, Iranian adult women had 5.8 ± 0.3 mg/dL higher HDL-C level than men. The analysis showed that the HDL-C levels will be changed at most 3 mg/dL from the age of 25 to 64 years. Furthermore, it was shown that approximately half of the men and one third of the women had HDL-C level less than 40 mg/DL. Also HDL-C level of more than 60% of the women was less than 50 mg/dL.

Conclusions

High level of HDL-C among Iranian adults was shown in this study which can be a major reason of increasing incidence of heart diseases in Iran. Hence, formulating policy regulations and interventions in Iranian lifestyle to reduce HDL-C levels should be among top priorities for health politicians.
Appendix
Available only for authorised users
Literature
1.
go back to reference Zhong S, Sharp DS, Grove JS, Bruce C, Yano K, Curb JD, Tall AR: Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J Clin Invest 1996, 97(12):2917–2923. 10.1172/JCI118751CrossRefPubMedPubMedCentral Zhong S, Sharp DS, Grove JS, Bruce C, Yano K, Curb JD, Tall AR: Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J Clin Invest 1996, 97(12):2917–2923. 10.1172/JCI118751CrossRefPubMedPubMedCentral
2.
go back to reference Miller G, Miller N: Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease. The lancet 1975, 305(7897):16–19. 10.1016/S0140-6736(75)92376-4CrossRef Miller G, Miller N: Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease. The lancet 1975, 305(7897):16–19. 10.1016/S0140-6736(75)92376-4CrossRef
3.
go back to reference Genest J: The Yin and Yang of High-Density Lipoprotein Cholesterol. J Am Coll Cardiol 2008, 51(6):643–644. 10.1016/j.jacc.2007.10.033CrossRefPubMed Genest J: The Yin and Yang of High-Density Lipoprotein Cholesterol. J Am Coll Cardiol 2008, 51(6):643–644. 10.1016/j.jacc.2007.10.033CrossRefPubMed
4.
go back to reference Alberti K, Zimmet P, Shaw J: Metabolic syndrome—a new world‒wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 2006, 23(5):469–480.PubMed Alberti K, Zimmet P, Shaw J: Metabolic syndrome—a new world‒wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 2006, 23(5):469–480.PubMed
5.
go back to reference Expert Panel on DetectionEvaluation THBCA: Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001, 285(19):2486–2497. 10.1001/jama.285.19.2486CrossRef Expert Panel on DetectionEvaluation THBCA: Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001, 285(19):2486–2497. 10.1001/jama.285.19.2486CrossRef
6.
go back to reference Bentley AR, Doumatey AP, Chen G, Huang H, Zhou J, Shriner D, Jiang C, Zhang Z, Liu G, Fasanmade O: Variation in APOL1 contributes to ancestry-level differences in HDLc-Kidney Function Association. Int J Nephrol 2012, 2012: 1–10.CrossRef Bentley AR, Doumatey AP, Chen G, Huang H, Zhou J, Shriner D, Jiang C, Zhang Z, Liu G, Fasanmade O: Variation in APOL1 contributes to ancestry-level differences in HDLc-Kidney Function Association. Int J Nephrol 2012, 2012: 1–10.CrossRef
7.
go back to reference Sharifi F, Mousavinasab S, Soruri R, Saeini M, Dinmohammadi M: High prevalence of low high-density lipoprotein cholesterol concentrations and other dyslipidemic phenotypes in an Iranian population. Metab Syndr Relat Disord 2008, 6(3):187–195. 10.1089/met.2008.0007CrossRefPubMed Sharifi F, Mousavinasab S, Soruri R, Saeini M, Dinmohammadi M: High prevalence of low high-density lipoprotein cholesterol concentrations and other dyslipidemic phenotypes in an Iranian population. Metab Syndr Relat Disord 2008, 6(3):187–195. 10.1089/met.2008.0007CrossRefPubMed
8.
go back to reference Hatmi Z, Tahvildari S, Motlag AG, Kashani AS: Prevalence of coronary artery disease risk factors in Iran: a population based survey. BMC Cardiovasc Disord 2007, 7(1):32–37. 10.1186/1471-2261-7-32CrossRefPubMedPubMedCentral Hatmi Z, Tahvildari S, Motlag AG, Kashani AS: Prevalence of coronary artery disease risk factors in Iran: a population based survey. BMC Cardiovasc Disord 2007, 7(1):32–37. 10.1186/1471-2261-7-32CrossRefPubMedPubMedCentral
9.
go back to reference Azizi F, Rahmani M, Ghanbarian A, Emami H, Salehi P, Mirmiran P, Sarbazi N: Serum lipid levels in an Iranian adults population: Tehran Lipid and Glucose Study. Eur J Epidemiol 2003, 18(4):311–319.CrossRefPubMed Azizi F, Rahmani M, Ghanbarian A, Emami H, Salehi P, Mirmiran P, Sarbazi N: Serum lipid levels in an Iranian adults population: Tehran Lipid and Glucose Study. Eur J Epidemiol 2003, 18(4):311–319.CrossRefPubMed
10.
go back to reference StataCorp: Stata Statistical Software. TX: StataCorp LP: Release 12. College Station; 2012. StataCorp: Stata Statistical Software. TX: StataCorp LP: Release 12. College Station; 2012.
11.
go back to reference Health NIo: Third Report of the National Cholesterol Education Program Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). NIH publication 2001, 1: 3670–3676. Health NIo: Third Report of the National Cholesterol Education Program Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). NIH publication 2001, 1: 3670–3676.
12.
go back to reference Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC: Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Curr Opin Cardiol 2006, 21(1):1–10. 10.1097/01.hco.0000200416.65370.a0CrossRefPubMed Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC: Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Curr Opin Cardiol 2006, 21(1):1–10. 10.1097/01.hco.0000200416.65370.a0CrossRefPubMed
13.
go back to reference Hosseini M, Carpenter R, Mohammad K: Growth of children in Iran. Ann Hum Biol 1998, 25(3):249–261. 10.1080/03014469800005612CrossRefPubMed Hosseini M, Carpenter R, Mohammad K: Growth of children in Iran. Ann Hum Biol 1998, 25(3):249–261. 10.1080/03014469800005612CrossRefPubMed
14.
go back to reference Ebrahimi M, Kazemi-Bajestani S, Ghayour-Mobarhan M, Ferns G: Coronary artery disease and its risk factors status in Iran: A review. Iran Red Crescent Med 2011, 13(9):610–623. Ebrahimi M, Kazemi-Bajestani S, Ghayour-Mobarhan M, Ferns G: Coronary artery disease and its risk factors status in Iran: A review. Iran Red Crescent Med 2011, 13(9):610–623.
15.
go back to reference Sharifi F, Mousavinasab S, Saeini M, Dinmohammadi M: Prevalence of metabolic syndrome in an adult urban population of the west of Iran. Exp Diabetes Res 2009, 13: 1–5.CrossRef Sharifi F, Mousavinasab S, Saeini M, Dinmohammadi M: Prevalence of metabolic syndrome in an adult urban population of the west of Iran. Exp Diabetes Res 2009, 13: 1–5.CrossRef
16.
go back to reference Heidari Z: Evaluation of Power of Components of Metabolic Syndrome for Prediction of its Development: A 6.5 Year Longitudinal Study in Tehran Lipid and Glucose Study (TLGS). Iran J Endocrinol 2010, 11: 1–2. Heidari Z: Evaluation of Power of Components of Metabolic Syndrome for Prediction of its Development: A 6.5 Year Longitudinal Study in Tehran Lipid and Glucose Study (TLGS). Iran J Endocrinol 2010, 11: 1–2.
17.
go back to reference Seftel H: The rarity of coronary heart disease in South African blacks. S Afr Med J 1978, 54(3):99–105.PubMed Seftel H: The rarity of coronary heart disease in South African blacks. S Afr Med J 1978, 54(3):99–105.PubMed
Metadata
Title
Serum HDL-C level of Iranian adults: results from sixth national Surveillance of Risk Factors of Non-Communicable Disease
Authors
Mostafa Hosseini
Iman Navidi
Mahmoud Yousefifard
Ramin Heshmat
Jalil Koohpayehzadeh
Fereshteh Asgari
Koorosh Etemad
Ali Rafei
Mohammad Mehdi Gouya
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Journal of Diabetes & Metabolic Disorders / Issue 1/2014
Electronic ISSN: 2251-6581
DOI
https://doi.org/10.1186/2251-6581-13-67

Other articles of this Issue 1/2014

Journal of Diabetes & Metabolic Disorders 1/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine